Evidence map›Paper›PMID 32148902›Full record

ReviewInterventional medicine & applied science2019

Strategic use of nanotechnology in drug targeting and its consequences on human health: A focused review.

Anand Maurya, Anurag Kumar Singh, Gaurav Mishra, Komal Kumari, Arati Rai, Bhupesh Sharma, Giriraj T Kulkarni, Rajendra Awasthi

Open access · diamondAbstract readReview
In one paragraph

Review in Interventional medicine & applied science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Designing of SiOFrontiers in cell and developmental biology · 2022
    Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Anand MauryaFaculty of Ayurveda, Department of Medicinal Chemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Anurag Kumar SinghCentre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Gaurav MishraFaculty of Ayurveda, Department of Medicinal Chemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Komal KumariDepartment of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Ajmer, India.
Arati RaiDepartment of Pharmacy, Hygia Institute of Pharmaceutical Education and Research, Lucknow, India.
Bhupesh SharmaAmity Institute of Pharmacy, Amity University, Noida, India.
Giriraj T KulkarniAmity Institute of Pharmacy, Amity University, Noida, India.
Rajendra AwasthiAmity Institute of Pharmacy, Amity University, Noida, India.
Amity University · INBanaras Hindu University · INCentral University of Rajasthan · INInstitute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the development of first lipid-based nanocarrier system, about 15% of the present pharmaceutical market uses nanomedicines to achieve medical benefits. Nanotechnology is an advanced area to meliorate the delivery of compounds for improved medical diagnosis and curing disease. Nanomedicines are gaining significant interest due to the ultra small size and large surface area to mass ratio. In this review, we discuss the potential of nanotechnology in delivering of active moieties for the disease therapy including their toxicity evidences. This communication will help the formulation scientists in understanding and exploring the new aspects of nanotechnology in the field of nanomedicine.

Indexed as

nanocarriersnanoformulationnanomedicinesnanotechnologytoxicity

Identifiers

PMID32148902
PMCPMC7044564
OpenAlexW2934174128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.